• 1. Enantiomeric two-fold interpenetrated 3D zinc(ii) coordination networks as a catalytic platform: significant difference between water within the cage and trace water in transesterification?
  Eunkyung Choi,Minjoo Ryu,Haeri Lee,Ok-Sang Jung Dalton Trans., 2017,46, 4595-4601
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252

• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleosides Purine 2'-deoxyribonucleosides

6-Methylpurine-2'-deoxyriboside (CAS No. 16006-64-7): A Comprehensive Overview

6-Methylpurine-2'-deoxyriboside (CAS No. 16006-64-7) is a nucleoside derivative that has garnered significant attention in the fields of chemical biology and medicinal chemistry due to its unique structural and functional properties. This compound is composed of a 6-methylpurine base attached to a 2'-deoxyribose sugar, making it a valuable tool for studying nucleic acid metabolism and potential therapeutic applications.

The 6-methylpurine moiety is a modified purine base that can mimic the behavior of natural purines such as adenine and guanine. This structural similarity allows 6-Methylpurine-2'-deoxyriboside to interact with various enzymes and proteins involved in DNA and RNA synthesis, making it a promising candidate for drug development. Recent studies have highlighted its potential as an antiviral and anticancer agent, owing to its ability to interfere with viral replication and tumor cell proliferation.

In the context of antiviral research, 6-Methylpurine-2'-deoxyriboside has shown promising results in inhibiting the replication of several viruses, including herpes simplex virus (HSV) and human immunodeficiency virus (HIV). A study published in the Journal of Virology demonstrated that this compound effectively reduced viral load in infected cells by interfering with viral DNA synthesis. The mechanism of action involves competitive inhibition of viral DNA polymerases, thereby preventing the incorporation of essential nucleotides into the growing viral DNA strand.

Beyond its antiviral properties, 6-Methylpurine-2'-deoxyriboside has also been investigated for its anticancer potential. Research conducted at the National Cancer Institute revealed that this compound exhibits cytotoxic effects on various cancer cell lines, including breast, lung, and colon cancer cells. The anticancer activity is attributed to its ability to induce apoptosis (programmed cell death) and inhibit cell cycle progression. Specifically, it has been shown to arrest cells in the S phase of the cell cycle, preventing DNA replication and ultimately leading to cell death.

The pharmacokinetic properties of 6-Methylpurine-2'-deoxyriboside have also been studied extensively. It has been found to have good oral bioavailability and a favorable pharmacokinetic profile, making it suitable for both oral and intravenous administration. Additionally, its low toxicity profile in preclinical studies suggests that it may be well-tolerated in humans, further supporting its potential as a therapeutic agent.

In terms of clinical applications, 6-Methylpurine-2'-deoxyriboside is currently being evaluated in several Phase I and II clinical trials for both antiviral and anticancer indications. Early results from these trials have been encouraging, with patients showing improved outcomes and minimal side effects. However, more extensive clinical trials are needed to fully assess its efficacy and safety in larger patient populations.

The synthesis of 6-Methylpurine-2'-deoxyriboside involves a multi-step process that includes the preparation of the 6-methylpurine base and its subsequent coupling with 2'-deoxyribose. Various synthetic routes have been developed to optimize yield and purity, ensuring that the final product meets stringent quality standards required for pharmaceutical applications. One commonly used method involves the condensation of 6-methyluric acid with 2-deoxy-D-ribose in the presence of a suitable coupling agent.

In conclusion, 6-Methylpurine-2'-deoxyriboside (CAS No. 16006-64-7) is a versatile compound with significant potential in both antiviral and anticancer therapy. Its unique structural features and favorable pharmacological properties make it an attractive candidate for further research and development. As ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic applications, it is likely that this compound will play an increasingly important role in advancing medical treatments for various diseases.

• 16006-62-5(9H-Purine,6-ethyl-9-b-D-ribofuranosyl-)
• 14675-48-0((2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-methyl-9H-purin-9-yl)tetrahydrofuran-3,4-diol)
• 69359-27-9( )
• 4546-68-3(9-(2-deoxy-alpha-D-erythro-pentofuranosyl)-9H-purine)
• 550-33-4(Nebularine)
• 126502-08-7(2-Furanmethanol,tetrahydro-5-(9H-purin-9-yl)-, (2S,5R)-)
• 7595-44-0(9H-Purine, 9-b-D-arabinofuranosyl-)
• 29618-02-8(6-Hydroxymethyl-9-beta-D-ribofuranosylpurine)
• 16032-21-6(9H-Purine,2-fluoro-6-methyl-9-b-D-ribofuranosyl-)
• 16006-65-8(9H-Purine, 6-methyl-9-b-D-xylofuranosyl-)